SNY Sep 2024 37.500 call
- GlobeNewswire
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
Sanofi completes acquisition of Inhibrx, Inc. Paris, May 30, 2024. Sanofi announced today the completion of its acquisition of Inhibrx, Inc. (“Inhibrx”). The acquisition adds SAR447537 (formerly INBRX-101) to Sanofi’s rare disease pipeline, underscoring the company’s commitment to pursuing differentiated and potential best-in-class medicines that build upon our existing strengths and capabilities. SAR447537 is a human recombinant protein that holds the promise of allowing alpha-1 antitrypsin def
- Simply Wall St.
3 High-Yielding Dividend Stocks On Euronext Paris With Up To 4.2% Yield
In recent trading sessions, France's CAC 40 Index has experienced a modest decline of 0.89%, reflecting broader European market uncertainties and mixed signals regarding future interest rate cuts. Amidst this backdrop, dividend stocks on Euronext Paris continue to attract attention for their potential to offer investors steady income streams in a fluctuating market environment. A key consideration for selecting strong dividend stocks involves not just the yield but also the sustainability...
- Zacks
Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag
The FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for transplant-ineligible newly diagnosed multiple myeloma. A decision is due on Sep 27, 2024.
